Heparin-induced thrombocytopenia (HIT) is an immune-mediated, prothrombotic complication of heparin therapy caused by IgG antibodies against platelet factor 4 (PF4)/heparin complexes. It occurs in 0.2%–5% of heparin-exposed patients and, paradoxically, causes thrombosis rather than bleeding — with thromboembolic complications developing in approximately 50% of confirmed cases if untreated. [5-7]
1. History
- Duration and type of heparin exposure (UFH vs. LMWH), including line flushes and heparin-coated catheters
- Timing of platelet drop: classic onset days 5–10 after heparin initiation; rapid-onset HIT can occur within hours if heparin exposure within the past 30–100 days [6]
- Symptoms of thrombosis: limb swelling/pain (DVT), dyspnea/chest pain (PE), focal neurologic deficits (stroke), abdominal pain (mesenteric ischemia)
- Skin changes at heparin injection sites (necrosis, erythematous lesions)
- Acute systemic reaction after IV heparin bolus (fever, chills, tachycardia, hypotension, dyspnea) — suggests rapid-onset HIT [6]
- Prior HIT history and prior heparin exposures (within 100 days)
- Important negatives: absence of spontaneous mucosal bleeding or petechiae (unusual in HIT despite thrombocytopenia) [8]
2. Alarm Features
- New thrombosis (venous or arterial) in a heparin-exposed patient with falling platelets
- Platelet count drop >50% from baseline, even if absolute count remains >100,000/μL
- Skin necrosis at heparin injection sites
- Acute systemic/anaphylactoid reaction post-heparin bolus
- Limb ischemia or gangrene
- Signs of PE, stroke, or mesenteric ischemia
- DIC with fibrinogen depletion (occurs in up to 20% of HIT patients) [7-8]
- Thrombocytopenia developing while on warfarin without a non-heparin anticoagulant bridge → risk of warfarin-induced venous limb gangrene [9]
3. Medications
Causative agents
- Unfractionated heparin (UFH) — highest risk (~10× higher than LMWH) [8]
- Low-molecular-weight heparin (LMWH) — lower risk but still causative
- Heparin flushes, heparin-coated catheters — often overlooked sources
Contraindicated in confirmed/suspected HIT
- All heparin products (UFH, LMWH) — must eliminate from all sources [10]
- Warfarin — must not be initiated until platelets ≥150,000/μL; if already on warfarin, reverse with vitamin K (warfarin depletes protein C and worsens the prothrombotic state) [7][10]
- LMWH — cross-reactivity with HIT antibodies approaches 90% [7]
- Platelet transfusions — avoid unless active bleeding or high bleeding risk [10]
Treatment agents (see Treatment Plan below)
4. Diet
- No specific dietary triggers or restrictions for HIT itself
- If transitioning to warfarin, standard vitamin K dietary counseling applies
- Ensure adequate hydration, particularly in patients with thrombosis or on continuous IV anticoagulant infusions
5. Review of Systems
- Vascular: limb swelling, pain, discoloration, claudication
- Pulmonary: dyspnea, pleuritic chest pain, hemoptysis
- Neurologic: headache, vision changes, focal weakness (stroke, cerebral sinus thrombosis)
- GI: abdominal pain, nausea, bloody stools (mesenteric ischemia)
- Skin: injection site pain, necrosis, erythematous plaques
- Cardiac: chest pain, palpitations (rare MI)
- Constitutional: fever, chills (especially with rapid-onset HIT)
6. Collateral History and Family History
- Confirm all sources of heparin exposure (pharmacy records, nursing documentation for line flushes, dialysis circuits)
- Prior episodes of HIT or unexplained thrombocytopenia during hospitalization
- Recent surgeries (especially cardiac or orthopedic — resets the immunologic clock) [6]
- Family history is generally not relevant — HIT is an acquired immune-mediated condition, not hereditary
- Social context: recent hospitalizations, procedures, or heparin exposure within the past 100 days
7. Risk Factors
- UFH > LMWH (10-fold higher risk with UFH) [8]
- Surgical patients > medical patients: cardiac surgery (1%–5%), orthopedic surgery (1%–5%), medical/obstetric patients (0.1%–1%) [6][8]
- Duration of heparin exposure: risk increases with >5 days of therapy
- Female sex — approximately twice the risk of males [8]
- Severity of trauma/surgery
- Post-cardiopulmonary bypass patients
- Prior heparin exposure within 100 days (risk of rapid-onset HIT) [6]
8. Differential Diagnosis
Cannot-miss diagnoses
- Thrombotic thrombocytopenic purpura (TTP) — schistocytes, low ADAMTS13, neurologic/renal involvement
- Disseminated intravascular coagulation (DIC) — elevated D-dimer, low fibrinogen, prolonged PT/aPTT
- Vaccine-induced immune thrombocytopenia and thrombosis (VITT) — similar anti-PF4 mechanism but without heparin exposure [11]
Common mimics
- Non-immune heparin-associated thrombocytopenia (Type I HIT) — mild, transient, non-immune platelet drop within first 2 days; benign, self-limited
- Sepsis-related thrombocytopenia — positive blood cultures, clinical sepsis
- Drug-induced thrombocytopenia (antibiotics, GPIIb/IIIa inhibitors, chemotherapy)
- Dilutional thrombocytopenia (massive transfusion, fluid resuscitation)
- Post-surgical hemodilution
- Mechanical platelet destruction (IABP, ECMO, VAD) [7]
- Pseudothrombocytopenia (EDTA-dependent platelet clumping) [5]
Distinguishing features of HIT: thrombocytopenia with thrombosis (not bleeding), typical timing (days 5–10), platelet nadir rarely <20,000/μL [7-8]
9. Past Medical History
- Prior HIT episodes (document clearly — lifelong heparin avoidance is generally recommended, though re-exposure may be considered in select cases with negative antibodies)
- History of VTE or arterial thrombosis
- Recent surgeries, especially cardiac/orthopedic
- Liver disease (affects argatroban dosing) or renal disease (affects bivalirudin/fondaparinux dosing)
- Malignancy (4Ts score not validated in cancer patients; alternative causes of thrombocytopenia common) [10]
10. Physical Exam
Vital signs
- Tachycardia, hypotension (PE, anaphylactoid reaction, DIC)
- Tachypnea, hypoxia (PE)
Focused exam
- Extremities: unilateral limb swelling, erythema, warmth (DVT); cool/pale/pulseless limb (arterial thrombosis); gangrene
- Skin: necrosis or erythematous lesions at heparin injection sites; livedo reticularis
- Lungs: decreased breath sounds, pleural rub (PE)
- Abdomen: tenderness (mesenteric ischemia, splanchnic vein thrombosis)
- Neurologic: focal deficits (stroke, cerebral venous sinus thrombosis)
- Notably absent: petechiae, purpura, and mucosal bleeding are rare despite thrombocytopenia [8]
11. Lab Studies
Initial labs
- CBC with platelet count — serial monitoring; look for >50% drop from peak (not just below normal range)
- PF4/heparin ELISA (immunoassay) — high sensitivity, moderate specificity; higher OD values (>1.5–2.0) correlate with higher likelihood of true HIT [6][12]
- Rapid immunoassay (e.g., chemiluminescent immunoassay) — faster turnaround if available
Confirmatory
- Serotonin release assay (SRA) — gold standard functional assay; confirms platelet-activating antibodies [10][12]
- P-selectin expression assay (PEA) — alternative functional assay [10]
- Heparin-induced platelet activation (HIPA) assay — used in some centers [13]
Additional labs
- Coagulation panel (PT, aPTT, fibrinogen, D-dimer) — assess for DIC
- Baseline aPTT and INR before starting alternative anticoagulation (HIT itself can elevate aPTT/INR) [7]
- LDH, haptoglobin, peripheral smear — rule out TTP/microangiopathy
Key point: A negative ELISA with a low 4Ts score effectively rules out HIT (NPV 97%–99%). [6] A positive ELISA with intermediate/high 4Ts should prompt functional assay confirmation. [12]
12. Imaging
- Lower-extremity duplex ultrasound — recommended for all confirmed HIT patients to screen for asymptomatic DVT [5][10]
- Upper-extremity ultrasound — if central venous catheter is present [5]
- CT pulmonary angiography — if PE suspected
- CT angiography of affected limb/mesentery — if arterial thrombosis or mesenteric ischemia suspected
- MRI/MRV brain — if cerebral venous sinus thrombosis suspected
- Imaging is unnecessary if HIT is ruled out by low 4Ts score and negative immunoassay
13. Special Tests
Scoring systems
The 4Ts Score is the recommended first-line clinical assessment tool per the ASH 2018 guidelines: [12]
- 4Ts Score: 0–3 = low probability (NPV 97%–99%); 4–5 = intermediate; 6–8 = high [6][10]
- HIT Expert Probability (HEP) Score: alternative scoring system; <3 negative, ≥3 positive [10]
- Post-CPB HIT Probability Score: for post-cardiac surgery patients [10]
Point-of-care
The following figure illustrates the diagnostic algorithm for suspected HIT:
14. ECG
- ECG is indicated if there is concern for:
- Acute MI (rare complication of HIT-related arterial thrombosis)
- Right heart strain from PE (S1Q3T3, right axis deviation, RBBB, T-wave inversions in V1–V4)
- Tachyarrhythmias
- Not routinely required for all suspected HIT cases unless clinical suspicion of cardiac involvement
15. Assessment
Clinical summary
HIT is a clinicopathologic syndrome requiring both a compatible clinical picture and laboratory confirmation of platelet-activating anti-PF4/heparin antibodies. [8] It is a medical emergency — the rate of thrombosis prior to treatment is approximately 5% per day. [8]
Severity stratification
- Isolated HIT (thrombocytopenia without thrombosis) — still requires anticoagulation due to high thrombotic risk
- HIT with thrombosis (HITT) — DVT, PE, arterial thrombosis, skin necrosis, limb gangrene
- Autoimmune HIT / delayed-onset HIT — thrombocytopenia begins or worsens after heparin discontinuation [9]
Complications
- VTE (most common): DVT, PE [6]
- Arterial thrombosis: stroke, MI, limb ischemia [7]
- Skin necrosis at injection sites (10%–20%) [7]
- DIC (up to 20%) [7]
- Adrenal hemorrhagic infarction (bilateral adrenal vein thrombosis)
- Warfarin-induced venous limb gangrene (if warfarin given without adequate non-heparin anticoagulation) [9]
In a contemporary multicenter cohort of 119 confirmed HIT patients, VTE occurred in 23%, arterial thromboembolism in 9%, major bleeding in 12.6%, and mortality in 18%. [14]
16. Treatment Plan
Immediate actions (do not wait for lab confirmation if intermediate/high 4Ts):
- Stop all heparin — including flushes, coated catheters, LMWH [10]
- Reverse warfarin with vitamin K if patient is on it [10]
- Start non-heparin anticoagulant at therapeutic dose [10]
First-line anticoagulants for hospitalized/critically ill patients — IV direct thrombin inhibitors (DTIs):
Alternative agents
- Fondaparinux (SC): weight-based dosing (5–10 mg daily); avoid if CrCl <30 mL/min; useful outside ICU [6][10]
- DOACs (rivaroxaban, apixaban): limited data for initial HIT treatment; reasonable for clinically stable patients without hemodynamically significant PE or limb-threatening thrombosis; rivaroxaban has the most supporting data [10]
Transition to long-term anticoagulation
- Warfarin: initiate only when platelets ≥150,000/μL; overlap with DTI/fondaparinux for ≥5–7 days; target INR ~4.0 before stopping argatroban (due to INR prolongation) [10]
- DOACs (preferred for transition): start when clinically stable; give first dose at time of DTI discontinuation or at next scheduled fondaparinux dose [10]
Duration of anticoagulation
- HIT without thrombosis: at least 4 weeks (some guidelines recommend up to 3 months) [5][10]
- HIT with thrombosis: at least 3 months [10]
Refractory/autoimmune HIT
- IVIG 1 g/kg IV daily × 2 days[10]
Platelet transfusions: avoid unless active bleeding or high bleeding risk with platelets <50,000/μL [10]
17. Disposition
Admission criteria
- All patients with suspected or confirmed HIT requiring IV anticoagulation (argatroban, bivalirudin)
- HIT with thrombosis (HITT)
- Hemodynamically unstable PE or limb-threatening ischemia
- DIC or active bleeding
- Need for aPTT monitoring and dose titration
Observation/step-down
Specialist consultation triggers
- Hematology — all confirmed or strongly suspected HIT cases
- Vascular surgery — limb ischemia or gangrene
- Interventional radiology — catheter-directed thrombolysis for massive DVT/PE
- Critical care — hemodynamic instability, DIC, multi-organ failure
18. Follow Up / Return Precautions
Follow-up timing
- Platelet count monitoring every 1–2 days until recovery (typically begins within days of heparin cessation; full recovery in 1–2 weeks)
- INR/aPTT monitoring during anticoagulant transition
- Hematology follow-up within 1–2 weeks of discharge
Return precautions (patient counseling)
- Return immediately for: new limb swelling/pain, chest pain, shortness of breath, sudden weakness or speech difficulty, abdominal pain, skin color changes in extremities
- Signs of bleeding: blood in urine/stool, unusual bruising, prolonged bleeding from cuts
Patient counseling points
- Lifelong documentation of HIT diagnosis — medical alert bracelet recommended
- Inform all future healthcare providers of HIT history before any procedure or hospitalization
- Heparin re-exposure may be considered in select cases (e.g., cardiac surgery) only when HIT antibodies are confirmed negative and under hematology guidance
- Expected recovery: platelet count typically normalizes within 4–14 days after heparin cessation; HIT antibodies become undetectable within ~100 days [6][11]
References
1. PF4/heparin Antibody Testing and Treatment of Heparin-Induced Thrombocytopenia in the Intensive Care Unit. — Wanat M, Fitousis K, Hall J, Rice L. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2013.
2. HITTING the Diagnosis: Testing for Heparin-Induced Thrombocytopenia in Cancer Patients. — Fenelus M, Peerschke EIB. American Journal of Clinical Pathology. 2018.
3. Predictive Value of the 4Ts Scoring System for Heparin-Induced Thrombocytopenia: A Systematic Review and Meta-Analysis. — Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Blood. 2012.
4. A High-Value Cost Conscious Approach to Minimize Heparin Induced Thrombocytopenia Antibody (HITAb) Testing Using the 4T Score. — Hasan M, Malalur P, Agastya M, et al. Journal of Thrombosis and Thrombolysis. 2016.
5. Thrombocytopenia: Evaluation and Management. — Gauer RL, Whitaker DJ. American Family Physician. 2022.
6. Heparin-Induced Thrombocytopenia. — Greinacher A. The New England Journal of Medicine. 2015.
7. Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review. — Salter BS, Weiner MM, Trinh MA, et al. Journal of the American College of Cardiology. 2016.
8. Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. — Linkins LA, Dans AL, Moores LK, et al. Chest. 2012.
9. Clinical Picture of Heparin-Induced Thrombocytopenia (HIT) and Its Differentiation From Non-Hit Thrombocytopenia. — Warkentin TE. Thrombosis and Haemostasis. 2016.
10. Cancer-Associated Venous Thromboembolic Disease. — Updated 2026-05-05. National Comprehensive Cancer Network.
11. Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia. — Treverton J, Arnold DM, Ivanov DG, et al. The New England Journal of Medicine. 2025.
12. American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Heparin-Induced Thrombocytopenia. — Cuker A, Arepally GM, Chong BH, et al. Blood Advances. 2018.
13. Accuracy of Diagnosing Heparin-Induced Thrombocytopenia. — Larsen EL, Nilius H, Studt JD, et al. JAMA Network Open. 2024.
14. Outcomes of Patients With Suspected Heparin-Induced Thrombocytopenia in a Contemporary Multicenter Cohort. — Nilius H, Sinitsa E, Studt JD, et al. Blood Advances. 2025.